Bruker Corp.

As of October 3, 2025, Bruker Corp. shows a mildly bearish technical trend, with key indicators like the weekly MACD and moving averages suggesting weakness, and it has underperformed the S&P 500 significantly over the past year.

As of October 3, 2025, Bruker Corp. shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and bearish monthly MACD, while no return data is available for comparison with the S&P 500.

As of October 3, 2025, Bruker Corp. is in a mildly bearish trend, with mixed technical indicators showing short-term outperformance against the S&P 500 but a significant year-to-date underperformance.

As of July 31, 2025, Bruker Corp. is in a bearish trend, indicated by negative signals from multiple technical indicators, and has significantly underperformed the S&P 500 with year-to-date and one-year returns of -43.24% and -50.19%, respectively.

As of June 30, 2025, Bruker Corp. is considered overvalued with a P/E ratio of 49, significantly higher than the peer average of 35.20, and despite a high dividend yield of 32.93%, its financial metrics and year-to-date return of -43.24% compared to the S&P 500's 12.22% indicate unfavorable positioning against its competitors.

As of February 13, 2025, Bruker Corp. is considered very expensive and overvalued with a P/E ratio of 49, low ROCE and ROE, and a year-to-date stock performance of -33.93%, significantly underperforming compared to its peers and the S&P 500.

As of June 2, 2025, Bruker Corp. is in a mildly bearish trend, with mixed signals from indicators like the weekly MACD being mildly bullish and the monthly MACD and moving averages remaining bearish.

As of March 2022, Bruker Corp.'s management team includes Dr. Frank Laukien as Chairman, President, and CEO, and Dr. William Linton as Lead Independent Director, along with independent directors Bonnie Anderson, Cynthia Friend, Marc Kastner, and John Ornell.

Bruker Corporation designs and manufactures scientific instruments and analytical solutions for the Pharmaceuticals & Biotechnology industry, with recent net sales of $801 million and a market cap of approximately $6.57 billion. Key financial metrics include a P/E ratio of 49.00 and a dividend yield of 33.64%.

As of Jun 18, Bruker Corp. has a market capitalization of $6.57 billion, with net sales of $3.45 billion and a net profit of $78.6 million over the last four quarters.